ReachMD’s Post

How can individualized management strategies reduce long-term complications and improve outcomes in patients with type 2 diabetes? In this educational program, Drs. Jennifer Green and Tina Thethi explore the importance of tailoring type 2 diabetes treatment to individual patient needs, including key considerations for selecting incretin-based therapies and the impact of weight loss on glycemic control. Their discussion illuminates the importance of a holistic, patient-centric approach in diabetes care, emphasizing shared decision-making and the incorporation of lifestyle modifications alongside pharmacological interventions. They also examine the concept of therapeutic inertia and its impact on diabetes management, emphasizing the importance of regular, proactive regimen evaluations to prevent long-term complications. Explore the importance of personalized care in type 2 diabetes management: https://ow.ly/j1vh50QFK8x #PatientCenteredCare #IncretinTherapies #DiabetesManagement

🩺 While more research is needed to fully understand the effects of red light therapy on diabetes, these preliminary results are promising. With further investigation, this non-invasive treatment could become a valuable tool in the fight against diabetes-related complications. #MedicalAdvancements #Healthcare 🌈 https://bit.ly/4c2zlMm

Final results from the prevalence phase of our phase IV clinical trial study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented today at the American Diabetes Association 84th Scientific Sessions. Read more: https://lnkd.in/g_SbwHCT #CortisolModulation #Diabetes #Type2Diabetes #ADASciSessions #Hypercortisolism

NabiQasim present you the upcoming Most Powerful, Fixed Dose Triple Combination in a single pill. Which offers Superior HbA1c Control with improved cardiovascular outcomes. Simplifying the treatment regimen & improving adherence making it an optimal choice for the management of Diabetes

REVOLUTIONIZING DIABETES MANAGEMENT: Insights from UKPDS The UKPDS follow-up, one of the longest clinical trials with over 80,000 person-years, underscores the critical importance of achieving near normoglycaemia (normal blood glucose level) right after a type 2 diabetes diagnosis: • Long-Term Benefits: Early intensive glycaemic control reduces the risk of death by 10%, myocardial infarction by 17%, and microvascular complications by 26%. • Cost-Effective Solutions: Utilized therapies are off-patent, affordable, and included in the WHO Essential Medicines list. • Legacy Effects: Early intervention with sulfonylurea, insulin, and metformin shows enduring health benefits even 24 years post-trial. These findings highlight the necessity of early and sustained glycaemic control to minimize lifetime complications and improve overall quality of life. Read the full study here: [The Lancet](https://lnkd.in/eP-nTexV) #DiabetesManagement #UKPDS #ClinicalTrials #GlycaemicControl #Type2Diabetes #Healthcare #MedicalResearch #LongTermHealth #CostEffective #PublicHealth #Metformin #Sulfonylurea #Insulin #WHO #EssentialMedicines #HealthEconomics #DiabetesCare

🔍 Just completed an insightful CME on a pressing issue in diabetes care: "The T2DM patient with kidney disease – What is going wrong? How can we do better?" 📚 With the prevalence of Type 2 Diabetes Mellitus (T2DM) on the rise, it's crucial to address the intricate interplay between diabetes and kidney health. This CME shed light on the complexities, challenges, and innovative approaches in managing patients at this critical intersection. Key takeaways: 🔹 Understanding the underlying mechanisms contributing to kidney disease in T2DM patients. 🔹 Exploring proactive strategies for early detection and intervention. 🔹 Harnessing the latest research and therapeutic advancements to optimize patient outcomes. Grateful for the opportunity to expand my knowledge and improve patient care. Let's continue striving for excellence in diabetes management! 💡 #DiabetesCare #KidneyHealth #ContinuousLearning

 Our first Institutional Insights video series is now available! "Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression," features insights from experts in diabetes management from Albany Medical Center who are using teplizumab with young patients to delay progression of type 1 diabetes from type 1 stage 2 to type 1 stage 3, or frank diabetes. They discuss type 1 diabetes screening, staging, and appropriate follow-up; explore the teplizumab mechanism of action; look at location options for infusion, and more.   https://lnkd.in/eiymhTgN

🩺 Unveiling the Link: Periodontal Therapy & Diabetes Management 🦷🩹 Did you know that in diabetic patients, periodontal therapy goes beyond oral health? 🦷✨ Here's the scoop: ✅ Improved Glycemic Control: Periodontal therapy can play a pivotal role in enhancing glycemic control for individuals with diabetes. ✅ Glycated Hemoglobin & Fasting Plasma Glucose: Witness a positive impact as it helps reduce Glycated hemoglobin and Fasting plasma glucose levels in type 2 diabetics. ✅ HbA1C Levels: Noteworthy reductions! Experience a significant drop in HbA1C levels at 3 months, with a continued positive trend at 6 months. 🌐 The connection between oral health and overall well-being is profound. Let's continue exploring these intersections for a healthier, holistic approach to diabetes management! 💙🌿 #DiabetesCare #OralHealthMatters #HolisticWellness #toshcare #hygienecoach #rdhstrong #microscope #businessofdentistry #dentalbusiness #elevateoralcare #dentalmicroscope #hygienemicroscope #dentalhygienistlife #healthcarehygienist #oralsystemichealth #oralsystemiclink

Breakthroughs in Type 1 Diabetes Research | Sernova | Airing on BNN Bloomberg Sernova is making significant strides in the treatment of type 1 diabetes with its cutting-edge clinical trials. Their groundbreaking approach has led to multiple patients achieving insulin independence and maintaining long-term blood sugar control within the non-diabetic range. This promising development could mark a major advancement in diabetes management, offering hope to millions affected by the condition. As Sernova continues its research, the future looks bright for those seeking more effective diabetes treatments. (TSX: SVA, OTCQB: SEOVF) Learn More: https://lnkd.in/eMT6FwZE #Diabetes #DiabetesTreatment #BloodSugarControl #ClinicalTrials #HealthcareStocks #StocksinFocus #StockstoWatch

In this Diabetes Care publication, we take a deep-dive into CGM data from two once-weekly icodec trials to answer pertinent clinical questions. Specifically, the hypoglycemia results are highly reassuring, given the context that the ONWARDS 2 and 4 trials included people with longstanding type 2 diabetes switching from basal alone or basal-bolus regimen ie those who would be deemed to be at high risk for hypoglycemia. Here's the free link to the full publication https://lnkd.in/gpqzPUYB